Trend Non-hallucinogenic neuroplastogens shift the field from the trip to the underlying biology

Summary

The Psychedelics and Healing Initiative reports that a new drug class engineered to promote neuroplasticity without hallucination, dissociation or supervised dosing is displacing the guided-experience model at the centre of psychedelic research. GWI argues these compounds promise outpatient-scale mental health treatment with fewer disqualifying contraindications.